- The Washington Times - Friday, December 2, 2005

From combined dispatches

A federal advisory panel determined yesterday that the first skin patch to treat attention-deficit hyperactivity disorder in children is both effective and safe, bringing the patch a step closer to regulatory approval.

However, the panel of independent specialists voted to recommend to the Food and Drug Administration that the patch’s label encourage its use as an alternative treatment for children with ADHD — in effect, saying doctors should prescribe it only if taking pills is too difficult for a child.

The unanimous vote by the FDA’s Psychopharmacologic Drugs Advisory Committee, saying the patch was acceptably safe, came after a formerly critical FDA reviewer reversed his opinion about the drug.

The agency will decide whether to approve the patch, which would be called Daytrana. It usually follows the advice of its advisory committees but is not required to do so. A decision is expected by Dec. 28, said a spokesman for British company Shire Pharmaceuticals, which developed the patch with Noven Pharmaceuticals of Miami.



An estimated 4.4 million children, ages 4 to 17, in 2003 were reported to have been diagnosed with ADHD, according to the most recent data from the Centers for Disease Control and Prevention.

Of those children, 2.5 million were reported to be taking medication for the disorder.

In documents posted by the FDA, agency reviewer Dr. Robert Levin had said that trials showed the patch produces troubling side effects too often to be considered safe. But yesterday, Dr. Levin told the committee he had reconsidered his opinion and now judged the drug was safe enough to approve.

The patch is designed to go on a child’s hip for nine hours, according to submissions by the companies that developed it. It releases into the body methylphenidate, which has been shown to help children with ADHD. It is the same stimulant that is in the drug Ritalin.

The patch is designed for children between the ages of 6 and 12. The developers said it is a way to treat ADHD in children for whom taking pills is difficult or unpleasant. Unlike a pill, it can be removed from the body if it causes harmful side effects.

Some children who received the patch during trials reported decreased appetites, headaches, insomnia, nausea and tics, the FDA said. These occurred more often than in children taking Concerta, a pill that uses methylphenidate, and others taking a placebo. Some in the patch test also had skin irritation.

In documents submitted to the FDA, the developers of the patch said it was safe and that problematic side effects were similar to those occurring in children who take methylphenidate orally.

Noven Pharmaceuticals spokesman Joseph Jones was not available to comment on the decision, the company said yesterday evening.

Citizens Commission on Human Rights International, a Los Angeles watchdog group for psychiatric human rights abuse, countered that the decision “put children’s lives at risk.”

“At a time when the FDA has recommended investigating all ADHD drugs for the potential to cause hallucinations, suicidal ideation, psychotic behavior, aggression and violence, the decision to approve a Ritalin patch is reprehensible,” spokeswoman Marla Filidei said.

Children and Adults With Attention-Deficit/Hyperactivity Disorder, a Landover nonprofit advocacy group with 20,000 members, said it would not issue any advice about the drug to its members until the FDA’s final ruling.

“But we support multiple types of treatments, including medications. Everybody is different. What works for one person, such as behavioral therapy or medications, will not work for another,” spokeswoman Ginny Thiersch said.

Shire spokesman Matt Cabrey said he was surprised that the FDA’s reviewer changed his mind and pleased with the outcome.

It is the second time Noven has submitted the patch to the FDA. In 2003, the agency rejected a previous proposal for a 12-hour patch and recommended Noven test the patch with a nine-hour application.

In the FDA documents, Dr. Levin had written the nine-hour patch “does not appear to be significantly more acceptable” than the 12-hour version. “Generally, it appears that the identical safety concerns remain,” he wrote.

Sign up for Daily Newsletters

Manage Newsletters

Copyright © 2021 The Washington Times, LLC. Click here for reprint permission.

Please read our comment policy before commenting.

 

Click to Read More and View Comments

Click to Hide